Preclinical Models in Prostate Cancer: Resistance to AR Targeting Therapies in Prostate Cancer
Wout Devlies, Florian Handle, Gaëtan Devos, Steven Joniau, Frank Claessens
Abstract
Prostate cancer is an androgen-driven tumor. Different prostate cancer therapies consequently focus on blocking the androgen receptor pathway. Clinical studies reported tumor resistance mechanisms by reactivating and bypassing the androgen pathway. Preclinical models allowed the identification, confirmation, and thorough study of these pathways. This review looks into the current and future role of preclinical models to understand resistance to androgen receptor-targeted therapies. Increasing knowledge on this resistance will greatly improve insights into tumor pathophysiology and future treatment strategies in prostate cancer.
Topics & Concepts
Prostate cancerMedicineAndrogen receptorProstateCancerAndrogenOncologyCancer researchBioinformaticsInternal medicineBiologyHormoneProstate Cancer Treatment and ResearchProstate Cancer Diagnosis and TreatmentHormonal and reproductive studies